Form 4: Eledon Pharmaceuticals CFO Acquires 525,032 Shares Through Option Vesting

Eledon Pharmaceuticals' Chief Financial Officer, Paul Little, acquired 525,032 shares of common stock through the vesting of a stock option.

Summary

• Paul Little, the Chief Financial Officer of Eledon Pharmaceuticals, acquired 525,032 shares of common stock.
• This acquisition occurred through the vesting of a stock option granted on May 1, 2023.
• The option vested due to the satisfaction of performance-based criteria on November 21, 2024.
• A portion of the option, representing 196,887 shares, also vested due to time-based criteria on November 1, 2024.
• The remaining 328,145 shares will vest in equal quarterly installments over three years, ending May 1, 2027.

Sentiment

Score: 7

Explanation: The document reflects a positive event for the executive, indicating that performance goals were met. It is a routine filing and does not suggest any negative sentiment.

Positives

• The vesting of the stock options indicates that performance targets were met.
• The CFO's increased stake in the company could align his interests with those of shareholders.

Future Outlook

The remaining 328,145 shares of the stock option will vest in substantially equal quarterly installments over a three-year period ending May 1, 2027.

Industry Context

This is a standard practice for incentivizing executives in publicly traded companies, aligning their interests with the long-term performance of the company.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the pharmaceutical industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule, with both performance and time-based components, is also typical for executive stock options.
• The size of the grant is not unusual for a CFO of a company of Eledon's size and stage.

Stakeholder Impact

• Shareholders may view the vesting of options as a positive sign of the company's performance.
• Employees may see this as a positive sign of the company's commitment to its executives.

Next Steps

• The remaining 328,145 shares will continue to vest quarterly until May 1, 2027.

Key Dates

Keywords

Eledon Pharmaceuticals, stock option, vesting, Paul Little, CFO, share acquisition, performance-based vesting, time-based vesting